Press coverage about Esperion Therapeutics (NASDAQ:ESPR) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Esperion Therapeutics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.623759411887 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- ESPR NOTICE: Pawar Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Esperion Therapeutics, Inc. Class … (digitaljournal.com)
- ESPR NOTICE: Pawar Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Esperion Therapeutics, Inc. Class Action – ESPR (finance.yahoo.com)
- Kessler Topaz Meltzer & Check, LLP – Deadline Reminder for Esperion Therapeutics, Inc. Investors – ESPR (finance.yahoo.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 – ESPR (finance.yahoo.com)
- Esperion Therapeutics Inc (ESPR) Short Interest Up 36.5% in May (americanbankingnews.com)
Shares of ESPR stock traded up $0.14 on Monday, reaching $39.97. 7,121 shares of the stock were exchanged, compared to its average volume of 1,017,370. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.68 and a beta of 2.37. Esperion Therapeutics has a 1-year low of $32.60 and a 1-year high of $82.68.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.17). During the same period last year, the business posted ($1.80) earnings per share. equities analysts forecast that Esperion Therapeutics will post -6.31 earnings per share for the current year.
Several research analysts recently issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating and set a $65.00 price objective (up from $55.00) on shares of Esperion Therapeutics in a research report on Wednesday, February 21st. Deutsche Bank lifted their price objective on Esperion Therapeutics to $100.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. BidaskClub downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 9th. UBS Group set a $75.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 16th. Finally, Needham & Company LLC restated a “strong-buy” rating and set a $94.00 price objective (up from $81.00) on shares of Esperion Therapeutics in a research report on Wednesday, February 21st. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $89.08.
In other news, major shareholder Target N. V. Biotech acquired 130,000 shares of the company’s stock in a transaction dated Monday, May 21st. The stock was acquired at an average cost of $40.11 per share, for a total transaction of $5,214,300.00. Following the acquisition, the insider now directly owns 2,872,964 shares in the company, valued at approximately $115,234,586.04. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech acquired 60,000 shares of the company’s stock in a transaction dated Thursday, June 7th. The shares were purchased at an average price of $37.79 per share, with a total value of $2,267,400.00. Following the completion of the acquisition, the insider now owns 3,072,964 shares in the company, valued at $116,127,309.56. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 300,000 shares of company stock valued at $11,901,900. Insiders own 14.50% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.